# Centene Corporation – Consensus ‘buy’ rating and 29.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/centene-corporation-consensus-buy-rating-and-29.9-upside-potential/4121126227
- Published: 2023-08-30T11:37:35+01:00
- Author: Charlotte Edwards

**Centene Corporation** which can be found using ticker (CNC) have now 19 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The range between the high target price and low target price is between 110 and 
71 suggesting an average Analsyt target price of $83.15. Given that the stocks previous
close was at $64.02 this now indicates there is a potential upside of 29.9%. The
day 50 moving average is $66.39 and the 200 day MA is $70.86. The company has a 
market cap of 34.89B. The current share price for the company is: 64.44 USD

 The potential market cap would be $45,319,356,063 based on the market consensus.

The company has a dividend yield of 1.57%. Other points of data to note are a P/
E ratio of 13.12, revenue per share of 247.62 and a 3.68% return on assets.

Centene Corporation is a healthcare company. The Company provides services to government-
sponsored and commercial healthcare programs, focusing on under-insured and uninsured
individuals. It provides a range of managed healthcare products and services, primarily
through Medicaid, Medicare, and commercial products. Its segments include Medicaid,
Medicare, Commercial and Other. It offers Medicaid and Medicare members (including
Medicare Prescription Drug Plans) as well as individuals and families served by 
the Health Insurance Marketplace and the TRICARE program. It also contracts with
other healthcare and commercial organizations to provide a variety of specialty 
services focused on treating the whole person. Medicaid program provides health 
insurance to low-income families and individuals with disabilities. Medicare is 
a federal health insurance program for people ages 65 and over, which also covers
people under 65 with certain disabilities and people with end-stage renal diseases.

Share on: